Paper Details

  1. Home
  2. Paper Details

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

Author: Al-KhatibShadi, BamjiAllison, BuggageRonald R, ChanChi Chao, DjalilianAli, Levy-ClarkeGrace A, LiZhuqing, MailmanMichelle, MellowSusan, NagarajanSudha, NussenblattRobert B, PetersonJan S, RobinsonRandy R, RoyChandra, SenHatice Nida, ShamesRichard S, SranPushpa, SrivastavaSunil, SuhlerEric B, TangMeina Tao, ThompsonDarby J S, UrseaRoxana, VelezGisela, WaldmannThomas A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Long-term daclizumab therapy, an anti-IL-2 receptor alpha treatment, was found to be effective in treating severe uveitis in lieu of standard immunosuppression. Subcutaneous daclizumab administration was also found to be a viable treatment strategy.
Paper Details　
Original Abstract of the Article :
Therapy for severe uveitis is frequently long-term immunosuppression using systemic corticosteroids and cytotoxic agents, but side effects make long-term therapy difficult. A long-term (>4 year) Phase I/II single armed interventional study using intravenous anti-IL-2 receptor alpha treatments (dacli...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0896-8411(03)00113-6

データ提供：米国国立医学図書館（NLM）

Harnessing the Power of Antibodies: Long-Term Treatment for Uveitis

Uveitis, an inflammatory condition affecting the eye, often requires long-term immunosuppression, which can lead to undesirable side effects. This study explores the potential of a humanized antibody, daclizumab, as a long-term treatment option for uveitis patients. The results demonstrate the feasibility and effectiveness of this approach, paving the way for a more targeted and sustainable treatment strategy.

Beyond the Horizon: Long-Term Daclizumab Therapy for Uveitis

The study highlights the successful long-term use of daclizumab in uveitis patients, with seven out of ten patients maintaining control of their uveitis for over four years while being tapered off their original immunosuppressive medications. This finding suggests that daclizumab can effectively replace conventional immunosuppressants, offering a potentially safer and more tolerable alternative. Imagine a desert oasis where a single, potent spring can sustain life for many years, much like daclizumab provides long-lasting relief from uveitis.

Expanding the Oasis: Subcutaneous Daclizumab Administration

The study also explores the potential of subcutaneous administration of daclizumab, demonstrating its clinical viability and suggesting that this route of administration may further enhance the convenience and accessibility of treatment. This finding opens up possibilities for a more patient-centered approach, allowing individuals to manage their uveitis with greater independence.

Dr. Camel's Conclusion

This research offers hope for uveitis patients seeking a long-term, effective, and tolerable treatment option. The success of daclizumab in managing uveitis highlights the power of targeted therapies in addressing complex medical conditions. Like a traveler discovering a hidden oasis in the heart of a vast desert, this research offers a promising alternative for uveitis patients, providing relief and improving their quality of life.

Date :
  1. Date Completed 2004-06-29
  2. Date Revised 2019-11-08
Further Info :

Pubmed ID

14599854

DOI: Digital Object Identifier

10.1016/s0896-8411(03)00113-6

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.